1887

Abstract

Resistance to antibiotics, especially clarithromycin, is the major cause of the failure to eradicate . There are few studies in children concerning fluoroquinolone activity against . Primary resistance to antibiotics including fluoroquinolones was studied in 55 strains isolated from Japanese children. DNA sequences of the gene in fluoroquinolone-resistant strains were determined. Twelve strains (21.8 %) were resistant to clarithromycin and three (5.5 %) were resistant to both levofloxacin and ciprofloxacin. Out of 12 clarithromycin-resistant strains, 11 (91.7 %) were susceptible to levofloxacin and ciprofloxacin. Sequence analysis in three fluoroquinolone-resistant strains showed point mutations of the gene at G271A, G271T and A272G, indicating mutations of the codon Asp91 in the fluoroquinolone-resistance-determining region of the DNA gyrase. The results suggest that fluoroquinolones should be considered as an option for second- or third-line eradication therapy in children.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.45642-0
2004-10-01
2019-11-21
Loading full text...

Full text loading...

/deliver/fulltext/jmm/53/10/JM531011.html?itemId=/content/journal/jmm/10.1099/jmm.0.45642-0&mimeType=html&fmt=ahah

References

  1. Adamek, R. J., Suerbaum, S., Pfaffenbach, B. & Opferkuch, W. ( 1998;). Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole and amoxicillin: influence on treatment outcome. Am J Gastroenterol 93, 386–389.
    [Google Scholar]
  2. Boyanova, L., Stancheva, I., Spassova, Z., Katzarov, N., Mitov, I. & Koumanova, R. ( 2000;). Primary and combined resistance to four antimicrobial agents in Helicobacter pylori in Sofia, Bulgaria. J Med Microbiol 49, 415–418.
    [Google Scholar]
  3. Cabrita, J., Oleastro, M., Matos, R. & 7 other authors ( 2000;). Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother 46, 1029–1031.[CrossRef]
    [Google Scholar]
  4. Croom, K. F. & Goa, K. L. ( 2003;). Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 63, 2769–2802.[CrossRef]
    [Google Scholar]
  5. European Helicobacter pylori Study Group ( 1997;). Current European concepts in the management of Helicobacter pylori infection: the Maastricht Consensus report. Gut 41, 8–13.[CrossRef]
    [Google Scholar]
  6. Falsafi, T., Mobasheri, F., Nariman, F. & Najafi, M. ( 2004;). Susceptibilities to different antibiotics of Helicobacter pylori strains isolated from patients at the pediatric medical center of Tehran, Iran. J Clin Microbiol 42, 387–389.[CrossRef]
    [Google Scholar]
  7. Fujimura, S., Kato, S., Kawamura, T. & Watanabe, A. ( 2002;). In vitro activity of rifampicin against Helicobacter pylori isolated from children and adults. J Antimicrob Chemother 49, 541–543.[CrossRef]
    [Google Scholar]
  8. Gendrel, D., Chalumeau, M., Moulin, F. & Raymond, J. ( 2003;). Fluoroquinolones in pediatrics: a risk for the patient or for the community? Lancet Infect Dis 3, 537–546.[CrossRef]
    [Google Scholar]
  9. Glupczynski, Y., Megraud, F., Lopez-Brea, M. & Andersen, L. P. ( 2001;). European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 20, 820–823.[CrossRef]
    [Google Scholar]
  10. Heep, M., Kist, M., Strobel, S., Beck, D. & Lehn, N. ( 2000;). Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 19, 538–541.[CrossRef]
    [Google Scholar]
  11. Kato, M., Yamaoka, Y., Kim, J. J. & 7 other authors ( 2000;). Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother 44, 2214–2216.[CrossRef]
    [Google Scholar]
  12. Kato, S., Fujimura, S., Udagawa, H., Shimizu, T., Maisawa, S., Ozawa, K. & Iinuma, K. ( 2002;). Antibiotic resistance of Helicobacter pylori strains in Japanese children. J Clin Microbiol 40, 649–653.[CrossRef]
    [Google Scholar]
  13. Lind, T., Megraud, F., Unge, P. & 9 other authors ( 1999;). The MACH 2 study: role of omeprazole in eradication of Helicobacter pylori with 1 week triple therapies. Gastroenterology 116, 248–253.[CrossRef]
    [Google Scholar]
  14. Megraud, F., Lehn, N., Lind, T. & 7 other authors ( 1999;). Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 43, 2747–2752.
    [Google Scholar]
  15. Moore, R. A., Beckthold, B., Wong, S., Kureishi, A. & Bryan, L. ( 1995;). Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob Agents Chemother 39, 107–111.[CrossRef]
    [Google Scholar]
  16. Murakami, K., Sato, R., Okimoto, T. & 7 other authors ( 2002;). Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther 16, 1933–1938.[CrossRef]
    [Google Scholar]
  17. National Committee for Health ( 1994;). Consensus conference: Helicobacter pylori in peptic ulcer disease. JAMA (J Am Med Assoc) 272, 65–69.[CrossRef]
    [Google Scholar]
  18. Nista, E. C., Candelli, M., Cremonini, F. & 10 other authors ( 2003;). Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther 18, 627–633.[CrossRef]
    [Google Scholar]
  19. Takada, S., Kato, M. & Takayama, S. ( 1994;). Comparison of lesions induced by intra-articular injections of quinolones and compounds damaging cartilage components in rat femoral condyles. J Toxicol Environ Health 42, 73–88.[CrossRef]
    [Google Scholar]
  20. Wang, G., Wilson, T. J. M., Jiang, Q. & Taylor, D. E. ( 2001;). Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori. Antimicrob Agents Chemother 45, 727–733.[CrossRef]
    [Google Scholar]
  21. Watanabe, Y., Aoyama, N., Shirasaki, D. & 8 other authors ( 2003;). Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy. Dig Liver Dis 35, 711–715.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.45642-0
Loading
/content/journal/jmm/10.1099/jmm.0.45642-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error